ECOR (electroCore) Change In Working Capital : $0.14 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is electroCore Change In Working Capital?

electroCore's change in working capital for the quarter that ended in Mar. 2025 was $-1.36 Mil.

electroCore's change in working capital for the fiscal year that ended in Dec. 2024 was $1.76 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

electroCore Change In Working Capital Historical Data

The historical data trend for electroCore's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore Change In Working Capital Chart

electroCore Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-1.76

1.63

2.04

0.82

1.76

electroCore Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															0.26	0.16	0.51	0.83	-1.36

electroCore Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

electroCore Change In Working Capital Related Terms

Thank you for viewing the detailed overview of electroCore's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

electroCore Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

43E0:Germany

Address

200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866

Website

https://www.electrocore.com

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Executives

Daniel S Goldberger	director, officer: Chief Executive Officer	24 CARPENTER ROAD, CHESTER NY 10918
Thomas J. Errico	director, 10 percent owner	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Joseph P Errico	director, 10 percent owner, officer: See Remarks	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein	director	205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber	director	205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner	officer: Chief Financial Officer	1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L	director	100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo	director	10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci	director	150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033